Pre-Clinical Tests of an Integrated CMOS Biomolecular Sensor for Cardiac Diseases Diagnosis

Coronary artery disease and its related complications pose great threats to human health. In this work, we aim to clinically evaluate a CMOS field-effect biomolecular sensor for cardiac biomarkers, cardiac-specific troponin-I (cTnI), N-terminal prohormone brain natriuretic peptide (NT-proBNP), and interleukin-6 (IL-6). The CMOS biosensor is implemented via a standard commercialized 0.35 μm CMOS process. To validate the sensing characteristics, in buffer conditions, the developed CMOS biosensor has identified the detection limits of IL-6, cTnI, and NT-proBNP as being 45 pM, 32 pM, and 32 pM, respectively. In clinical serum conditions, furthermore, the developed CMOS biosensor performs a good correlation with an enzyme-linked immuno-sorbent assay (ELISA) obtained from a hospital central laboratory. Based on this work, the CMOS field-effect biosensor poses good potential for accomplishing the needs of a point-of-care testing (POCT) system for heart disease diagnosis.

[1]  J. Mehta,et al.  Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. , 2007, The American journal of cardiology.

[2]  Baris Gencer,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .

[3]  T. Ohsaka,et al.  Voltammetric detection of uric acid in the presence of ascorbic acid at a gold electrode modified with a self-assembled monolayer of heteroaromatic thiol , 2003 .

[4]  G. Geng,et al.  Interleukin-6 (IL-6) -174G/C genomic polymorphism contribution to the risk of coronary artery disease in a Chinese population. , 2016, Genetics and molecular research : GMR.

[5]  A. Khera,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[6]  Fred S Apple,et al.  National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. , 2007, Circulation.

[7]  Bei Cheng,et al.  The clinical value of inflammatory biomarkers in coronary artery disease: PTX3 as a new inflammatory marker , 2017, Experimental Gerontology.

[8]  A. Archakov,et al.  Quartz crystal microbalance for the cardiac markers/antibodies binding kinetic measurements in the plasma samples , 2014 .

[9]  Ajay Agarwal,et al.  Label-free electrical detection of cardiac biomarker with complementary metal-oxide semiconductor-compatible silicon nanowire sensor arrays. , 2009, Analytical chemistry.

[10]  E. Zakynthinos,et al.  Inflammatory biomarkers in coronary artery disease. , 2009, Journal of cardiology.

[11]  E. Yeong,et al.  Prognostic Significance of Left Ventricular Diastolic Function in Burn Patients , 2012, Shock.

[12]  P. Millner,et al.  Mixed self-assembled monolayer (mSAM) based impedimetric immunosensors for cardiac troponin I (cTnI) and soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) , 2012 .

[13]  Lateef Ahmad,et al.  A new HPLC method for the simultaneous determination of ascorbic acid and aminothiols in human plasma and erythrocytes using electrochemical detection. , 2011, Talanta.

[14]  Yen-Hung Lin,et al.  A microfluidic device integrating dual CMOS polysilicon nanowire sensors for on-chip whole blood processing and simultaneous detection of multiple analytes. , 2016, Lab on a chip.

[15]  Jean-Philippe Charrier,et al.  Isoelectric point determination of cardiac troponin I forms present in plasma from patients with myocardial infarction. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[16]  Carlos Duarte-Guevara,et al.  On-chip electrical detection of parallel loop-mediated isothermal amplification with DG-BioFETs for the detection of foodborne bacterial pathogens , 2016 .

[17]  S. Lerakis,et al.  Inflammation in Coronary Artery Disease , 2014, Cardiology in review.

[18]  M. Andrades,et al.  Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography , 2017, Diabetology & Metabolic Syndrome.

[19]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[20]  Maarten L. Simoons,et al.  The third universal definition of myocardial infarction , 2013 .

[21]  C. Cobbaert,et al.  The additive value of N-terminal pro-B-type natriuretic peptide testing at the emergency department in patients with acute dyspnoea. , 2009, European journal of internal medicine.

[22]  Shuilin Huang,et al.  Plasma levels of tumor necrosis factor-&agr; and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase , 2011, Critical care medicine.

[23]  Sung-Jin Choi,et al.  A Highly Responsive Silicon Nanowire/Amplifier MOSFET Hybrid Biosensor , 2015, Scientific Reports.

[24]  W Frank Peacock,et al.  State of the art: Using natriuretic peptide levels in clinical practice , 2008, European journal of heart failure.

[25]  Tetsuya Osaka,et al.  Fabrication of stable antibody-modified field effect transistors using electrical activation of Schiff base cross-linkages for tumor marker detection. , 2011, Biosensors & bioelectronics.

[26]  C-T Lin,et al.  A CMOS wireless biomolecular sensing system-on-chip based on polysilicon nanowire technology. , 2013, Lab on a chip.

[27]  Tina M. Battaglia,et al.  Quantitative measurement of cardiac markers in undiluted serum. , 2007, Analytical chemistry.

[28]  J. Burnett,et al.  NT-proBNP: The Gold Standard Biomarker in Heart Failure. , 2016, Journal of the American College of Cardiology.